The U.S. Food and Drug Administration recently announced two developments that, taken together, mark a meaningful shift in how the agency is operationalizing artificial intelligence (AI) at the FDA: an expansion of its internal AI capabilities and the completion of a long‑running effort to consolidate FDA data systems into a unified platform. This announcement was framed as infrastructure—not as a new policy or regulatory position. That distinction matters. From FDA AI pilo

In medical and regulatory writing workflows, discussions about AI often default to speed—draft faster, iterate faster, review faster. From the perspective of regulatory reviewers, however, speed alone rarely improves outcomes. Reviewers are responsible for evaluating safety, efficacy, and scientific integrity, and those responsibilities depend far more on context, traceability, and confidence than on how quickly a document was produced. Reframing AI’s role around the reviewe

Regulatory review has traditionally been treated as a discrete phase—an endpoint where documents move from creation to evaluation, often triggering compressed timelines and late-stage rework. In practice, regulatory decisions are rarely made at a single moment. They emerge gradually, as evidence, context, and interpretation come into focus. Regulatory review automation enabled by AI does not replace this process or accelerate decisions indiscriminately. Instead, it reshapes